HRT and Rheumatoid Arthritis: What Changes If You Already Have RA

HRT and rheumatoid arthritis are not automatically incompatible. Four randomized RA trial cohorts found no statistically significant worsening in measured RA disease activity, but RA already raises clot risk and a 2026 observational study found higher VTE rates after menopausal hormone therapy started. The decision is not “RA means no.” It is route, medication, and risk review.

That last sentence is the part almost nobody has written about yet. We will get to it in full, with the actual numbers, because it changes what you should ask for — not whether you are allowed to ask.

Here is what most pages get wrong. There are three different questions hiding inside “HRT and rheumatoid arthritis,” and they have three different answers:

1. Does hormone therapy raise the chance of developing RA? Observational studies show a small association. They do not prove hormone therapy causes RA.
2. Does hormone therapy make existing RA worse? The randomized studies did not find statistically significant worsening in the RA outcomes they measured.
3. Does hormone therapy treat RA? No. It is not a disease-modifying antirheumatic drug and should never be sold as one.

If you already have rheumatoid arthritis, the frightening incidence headline is not the same question as the one you are living. Your real question is what RA, your medications, your clot history, and the estrogen route change about a menopause-treatment decision.

Best for / not your starting point

This page is for you if	This is not your starting point if
You have diagnosed RA and have been told hormone therapy may be “off the table”	You have new one-sided leg swelling, sudden breathlessness, chest pain, coughing blood, or fainting — seek emergency care
You take methotrexate, a biologic, a JAK inhibitor, or long-term glucocorticoids	Your joints are newly swollen, hot, or progressively worse and RA has not been assessed — rheumatology comes first
You saw the “HRT raises RA risk 46%” headline and panicked	You have a personal history of DVT, pulmonary embolism, stroke, or heart attack — start with in-person risk review and HRT and blood clots
You need to separate menopausal joint symptoms from inflammatory disease activity	You have lupus, antiphospholipid syndrome, or known positive antiphospholipid antibodies — rheumatology must be involved before a hormone decision
You are facing both menopause symptoms and the bone consequences of RA or glucocorticoids	You have unexplained vaginal bleeding — that needs evaluation before systemic hormone therapy

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Can you take HRT if you have rheumatoid arthritis?

Answer capsule: Rheumatoid arthritis by itself is not an automatic prohibition on menopausal hormone therapy. The American College of Rheumatology supports HRT when otherwise indicated for postmenopausal women with rheumatic disease who do not have lupus or positive antiphospholipid antibodies and have no ordinary HRT contraindication. The 2026 clot data make individualized route and medication review essential.^[1]

That is the clean answer. RA changes the workup; it does not erase the option.

The useful way to think about this is not a single green light or red light. It is a set of gates that tell you which clinician should answer which part.

The RA + HRT decision map

Your situation	What the evidence changes	Best starting point	The question that resolves the next step
RA is stable, no personal clot history, no known aPL/APS	RA is not an automatic HRT barrier, but baseline VTE risk is higher than in the general population	Menopause clinician, with your full medication list	“Which route are you recommending, and why in my RA risk context?”
You use a JAK inhibitor such as tofacitinib, baricitinib, or upadacitinib	JAK-inhibitor labeling already carries thrombosis warnings; European/UK materials specifically name HRT as a VTE risk factor	Rheumatologist first or coordinated rheumatology/menopause review	“Does this combination make a non-oral route or a nonhormonal option the better starting point?”
You have active or poorly controlled RA	Higher disease activity is associated with higher VTE risk and can mimic or amplify menopause symptoms	Rheumatologist first	“How active is my RA now, and what must be stabilized before we decide on HRT?”
You have a personal history of DVT, PE, stroke, or heart attack	Current systemic estrogen labeling treats these histories as major contraindication or risk-review issues	In-person clinician; do not rely on an online intake alone	“Which menopause treatments remain appropriate given my vascular history?”
You have lupus, APS, or known positive antiphospholipid antibodies	ACR recommendations become substantially more restrictive	Rheumatology-led decision	“Which antibody category am I in, and does that rule out systemic HRT?”
Your main problem is vaginal dryness, painful sex, or urinary symptoms	Low-dose vaginal estrogen has much lower systemic exposure and is a separate decision from systemic HRT	Menopause, gynecology, or primary-care clinician	“Are my symptoms local enough that low-dose vaginal therapy could do the job?”
You take glucocorticoids for more than three months	You need a separate glucocorticoid-induced osteoporosis assessment; HRT does not replace it	Rheumatology or primary care plus menopause care	“What is my fracture-risk plan, separate from my menopause plan?”
You have new swelling or have never been diagnosed with RA	Menopause symptoms and inflammatory arthritis overlap, but delaying RA treatment can allow permanent joint damage	In-person assessment before HRT routing	“Do these symptoms meet the pattern of inflammatory arthritis?”

This is a decision framework, not an eligibility test. It does not tell you that you can or cannot take a prescription. It tells you what has to be resolved before anyone gives you an honest answer.

What we actually verified for this page

We read the primary and official sources rather than copying another health article. The verification set includes:

• the four RA-specific randomized trial cohorts conducted between 1993 and 2003, including separate disease-activity and bone reports from the same 200-woman Hall cohort;
• the Women's Health Initiative randomized analysis, which came from a 27,347-woman parent trial but included only 63 women with existing RA and 105 incident RA cases;
• the July 2026 UK matched cohort on menopausal hormone therapy and VTE in women with RA;
• the 2026 meta-analysis on incident RA risk, the 2024 UK Biobank cohort, and the Korean national cohort behind the headlines;
• the 2020 ACR reproductive-health guideline and its detailed menopause appendix;
• the current 2022 ACR guideline for glucocorticoid-induced osteoporosis;
• current FDA, EMA, MHRA, and US prescribing materials relevant to systemic estrogen and JAK inhibitors;
• provider-stated pricing, insurance, visit model, medication, and availability details checked on September 3, 2026.

What we did not do: we did not interview patients, complete a paid provider consult, or have this page reviewed by a clinician. We do not publish a made-up medical review, patient story, or numeric provider score. Where the published evidence cannot answer a question, we say so instead of quietly turning uncertainty into permission.

---

Does menopause actually make rheumatoid arthritis worse?

Answer capsule: Menopause is associated with worse physical function in women whose RA began before menopause. In an 8,189-woman longitudinal study, postmenopausal status was associated with a 0.68-point worse score on the 0-to-3 Health Assessment Questionnaire after adjustment. A 2026 observational study found only a very small functional advantage among estrogen users — not proof that estrogen treats RA.^[2][3]

If your RA changed when your periods did, you are not imagining the timing. The timing appears in the data. What the data cannot do is tell us that falling estrogen alone caused the change.

The 2018 study followed women whose rheumatoid arthritis had already started before menopause. Of 8,189 women, 2,005 were premenopausal, 611 transitioned through menopause during follow-up, and 5,573 were postmenopausal. After adjustment, postmenopausal women had a Health Assessment Questionnaire score 0.68 points worse than premenopausal women, and their functional decline accelerated after menopause.^[2]

The part of that study nobody quotes

The same analysis found that three markers of greater lifetime reproductive-hormone exposure were associated with less functional decline:

• prior HRT use;
• prior pregnancy;
• a longer reproductive lifespan.

That does not turn the paper into an HRT trial. Women who use HRT differ from women who do not, and a reproductive-history association cannot establish a treatment effect. But the signal points away from the idea that estrogen exposure automatically makes existing RA worse.

The 2026 update is encouraging — and much smaller than the headline version

A new longitudinal analysis published in 2026 matched 4,123 postmenopausal estrogen-replacement users to 4,123 non-users with RA. Estrogen use was associated with a 0.02-point lower HAQ score after adjustment, with a larger association among women who began within five years of menopause.^[3]

That is statistically measurable and clinically modest. A 0.02-point difference on a 0-to-3 disability scale is not a transformation, and this was observational research rather than a randomized treatment trial. The honest reading is: the newer data do not show functional harm, and they hint at a small benefit, but they do not make estrogen an RA therapy.

Why RA and menopause collide in the first place

RA is much more common in women than men, and major hormonal transitions have long been linked with changes in disease activity. Pregnancy often reduces RA activity, while the postpartum period is a recognized time of increased flare risk. Those patterns explain why clinicians and researchers keep asking about reproductive hormones; they do not prove a single-hormone mechanism.^[4][5]

Your body’s timing feels suspicious because it is scientifically suspicious. It just is not simple.

---

Will HRT cause a rheumatoid arthritis flare?

Answer capsule: Four RA-specific randomized trial cohorts tested estrogen-containing hormone therapy in women with established rheumatoid arthritis. None found statistically significant worsening in the RA disease-activity measures they reported. Some outcomes improved, one trial found no disease benefit, and the studies were small, old, and conducted before modern biologics and JAK inhibitors became routine.^[6][7][8][9]

This is the question that keeps women awake, so let’s take it apart properly.

The reassuring part is real. The limitations are real too. A trustworthy page has to print both.

Every randomized RA trial cohort, without counting the same women twice

Randomized cohort	What researchers tested	Participants	What the trial actually found
van den Brink, 1993	Oral estradiol valerate versus placebo for 52 weeks	40 randomized; 33 completed	No statistically significant between-group benefit in articular indices, pain, ESR, or daily function. This is the clean negative trial.[6]
MacDonald, 1994	Transdermal estradiol-based HRT versus placebo for 48 weeks	62	HRT was well tolerated; wellbeing, articular index, and lumbar-spine bone density improved. ESR and CRP did not show a disease-modifying effect.[7]
Hall, 1994	Transdermal estradiol versus placebo on top of usual RA treatment; disease and bone outcomes were published separately	200	No significant overall disease-activity benefit. Women who achieved higher estradiol levels had improvements in tenderness, pain, and morning stiffness. The bone report found lumbar-spine BMD rose 2.22% with HRT versus a 1.19% loss in controls. These were two papers from one cohort, not two trials.[8][10]
Forsblad D’Elia, 2003	HRT plus calcium and vitamin D versus calcium and vitamin D for two years	88 with active RA	DAS28, inflammatory measures, and BMD improved; radiographic progression was slower in the subgroup whose joint damage was progressing. The trial was small and used an older regimen.[9]

The trial table gives you the strongest reassuring fact on this page: randomization did not produce a signal of worsening RA activity.

It does not let us say that no participant ever experienced a flare. “Flare” was not a uniform, prospectively reported endpoint across all four cohorts. The accurate claim is narrower and stronger because it is true: none of the randomized cohorts found statistically significant worsening in the RA measures they studied.

The Women's Health Initiative sounds bigger than it was for RA

The WHI hormone trials randomized 27,347 women, which looks enormous in a headline. But the RA analysis identified only 63 women with existing RA and 105 women who developed RA. Among the existing-RA subgroup, hormone therapy did not produce a statistically significant difference in reported joint pain or hand and foot swelling. For incident RA, the hazard ratio was 0.74 (95% CI 0.51–1.10) — a non-significant result pointing toward lower, not higher, incidence.^[11]

That is useful randomized evidence. It is not 27,347 women with RA.

The trial that found nothing belongs here on purpose

The van den Brink study found no meaningful RA benefit after a year of oral estradiol. Nothing on joint indices. Nothing on ESR. Nothing on daily function.

We are printing it because a page that only shows you the encouraging trials is not worth trusting.

The honest verdict across the randomized evidence

HRT did not worsen measured RA disease activity in these trials, and some women had better symptoms or bone outcomes. It is still not reliable or modern enough to prescribe as an RA treatment.

A systematic review published online in 2025 and in print in 2026, covering 57 studies and nearly four million participants, found no overall association between HRT and generalized musculoskeletal pain — pooled risk ratio 1.00 (95% CI 0.96–1.04) — and found the arthritis evidence too heterogeneous for a clean pooled treatment conclusion.^[12]

Hormone therapy treats menopause. Sometimes joints feel better. That is welcome, but it is not the plan.

Does that sound like your situation? If your RA is stable and you have been assuming menopause treatment is automatically unavailable, use Find My HRT Path to see your best-fit online starting route, why it fits, and two backup routes. The tool does not decide whether HRT is safe for you; it tells you where the decision should start.

---

Does HRT cause rheumatoid arthritis? What the “46%” headline measured

Answer capsule: A 2024 UK Biobank study associated prior HRT use with a 46% higher rate of developing RA. A 2026 meta-analysis of five observational studies across 22.3 million person-years found a much smaller pooled association of 15%. Neither can prove causation, and neither answers whether HRT worsens disease in a woman who already has RA.^[13][14]

Let’s take the scary number seriously first, because you deserve that.

The study behind the headline

Jiang and colleagues followed 223,526 women in UK Biobank for a median of 12.39 years. During follow-up, 3,313 developed RA. Ever-use of HRT was associated with an adjusted hazard ratio of 1.46 (95% CI 1.35–1.57).^[13]

That is a real result in a peer-reviewed prospective cohort. It is also an association, not a randomized exposure.

The number the headline skipped

The 2026 systematic review and meta-analysis was published in Seminars in Arthritis and Rheumatism. It pooled five observational studies covering 22,291,843 person-years and reported:^[14]

• overall HRT use: rate ratio 1.15 (95% CI 1.10–1.21);
• current use: 1.18 (1.00–1.37);
• former use: 1.11 (0.94–1.32), not statistically significant;
• four or more years of use: 1.19 (1.07–1.33).

So the single-study headline was 46%. The pooled observational estimate was 15%.

We are not converting that 15% into a personal “one in X” number. Doing that would require borrowing a background incidence rate from a different population and pretending it maps cleanly onto you. It does not.

The pattern inside the UK Biobank paper is more complicated than “estrogen causes RA”

Exposure in the same cohort	Association with incident RA
Ever used HRT	HR 1.46
Menopause before age 45	HR 1.46
Hysterectomy	HR 1.40
Fewer than 33 reproductive years	HR 1.39
Oophorectomy	HR 1.21
Each additional year of HRT use	HR 1.02

Taking estrogen and losing ovarian exposure early were both associated with higher RA incidence in the same dataset. That does not cancel either association. It does make a one-line causal story hard to defend.

Our editorial reading: indication bias, reproductive history, healthcare contact, and early undiagnosed symptoms are doing visible work in these data. The weak per-year duration association also does not look like a simple, steep dose-response. That interpretation is ours; the numbers are the study’s.^[13]

The Korean cohort explains one way the association can be created

In a national cohort of more than 1.3 million postmenopausal women, longer HRT exposure was associated with a modest increase in seropositive RA diagnosis. The authors discussed the possibility that menopausal musculoskeletal symptoms or early, not-yet-diagnosed RA could prompt an HRT prescription before the eventual RA diagnosis.^[15]

That is not proof that every association is reverse causation. It is a plausible pathway: aching hands lead to a menopause visit, HRT starts, clearer inflammatory signs appear later, and the later diagnosis is counted after exposure.

The randomized evidence points the other way — without reaching significance

In the WHI randomized analysis, incident RA had a hazard ratio of 0.74, with a confidence interval crossing 1.0. That means the trial did not show a statistically reliable increase or decrease.^[11]

The correct bottom line is not “HRT prevents RA.” It is this: the incidence signal is observational, modest in pooled data, and inconsistent with the direction of the randomized estimate.

The British Menopause Society reached the practical conclusion women actually need: an observational incidence paper is not a reason to deny needed HRT automatically to a woman with RA.^[16]

---

What did the 2026 clot study find in women with RA using HRT?

Answer capsule: A 2026 UK cohort compared 2,187 women with RA who started menopausal hormone therapy with 8,205 matched women with RA who did not. VTE rates were 6.49 versus 3.30 per 1,000 person-years, with an adjusted hazard ratio of 1.92. The study was observational, Pfizer-sponsored, and unable to compare pills with patches.^[17]

This is the honest hard part of this page, and we are not going to bury it.

Everything above is reassuring. This is not. So here it is in full.

The study and the numbers

The researchers used English primary-care records linked to hospital and mortality data from 2001 through 2021. They matched women aged 40 to 79 who had RA and initiated menopausal hormone therapy to women with RA who did not initiate it.^[17]

What the researchers measured	Result
Women with RA starting MHT	2,187
Matched women with RA not starting MHT	8,205
VTE events in the MHT group	27
VTE events in the comparison group	49
VTE incidence in the MHT group	6.49 per 1,000 person-years
VTE incidence in the comparison group	3.30 per 1,000 person-years
Adjusted hazard ratio for VTE	1.92 (95% CI 1.19–3.12)
Adjusted hazard ratio for DVT	2.26 (95% CI 1.26–4.05)
Route among starters	47.4% oral; 52.4% transdermal
Could the study compare pill versus patch outcomes?	No — too few events

What the absolute difference means

The observed rate difference was 3.19 additional VTE events per 1,000 person-years. The paper expressed that as one additional event per 313 person-years of treatment under the observed rates.^[17]

That is not the same as saying “one in every 313 women will have a clot.” Person-years combine people and time, and this was not a randomized trial. The clearest plain-language version is: the study observed about three additional clot events for every 1,000 years of exposure across women in the treated cohort.

The limitations that decide how much weight to give it

1. It was observational. Matching and statistical adjustment reduce measured differences; they do not erase unmeasured differences between women who begin MHT and women who do not.
2. It could not answer the route question. Roughly half of the starters used oral therapy and half used transdermal therapy, but the event count was too small for a reliable comparison.
3. It could not give a clean product-level answer. Estrogen-only and estrogen-plus-progestogen regimens were combined for the main analysis.
4. The population was about 93% White. That limits how confidently the rate estimates travel to more diverse populations.
5. Pfizer sponsored the study. Pfizer employees were among the authors, and the funder was involved in study design, analysis, and manuscript preparation. That does not invalidate the data. It is a material conflict readers deserve to see beside the result.^[17]

What it does not mean

It does not prove MHT caused every clot. It does not prove transdermal estradiol is safe in RA. It does not prove that every woman with RA should avoid HRT. And it does not erase the randomized disease-activity studies, because those studies asked a different question.

Here is the pivot, and it is the whole point of this page

HRT for a woman with rheumatoid arthritis is not a yes-or-no decision. It is a route-and-review decision.

That was true before this study. It is more true now. And it is genuinely useful bad news, because “which route, which medication, and who reviews it?” is a question with a process. “Is HRT safe for me?” is not a question any article can answer from a distance.

What you actually need is four specific things:

1. which evidence applies to existing RA rather than developing RA;
2. whether your RA medication adds a clot concern;
3. what your own baseline vascular history looks like;
4. which specialist owns each part of the decision.

Those four things turn an unanswerable fear into a short, specific appointment.

If you have had a DVT, pulmonary embolism, stroke, or heart attack, stop using this page as an online-care green light. Read HRT and blood clots and start with an in-person clinician who can review your full history.

If clot risk is the part that has you stuck: use Find My HRT Path to see whether your situation routes toward online care or an in-person starting point, then bring the questions in this page to the clinician. The tool takes about 90 seconds, requires no email, and does not make a treatment decision.

---

Is a patch safer than a pill if you have rheumatoid arthritis?

Answer capsule: No study has compared oral and transdermal estrogen head-to-head within RA. General-population evidence and the ACR rheumatic-disease guideline make transdermal estrogen a reasonable route to discuss because it avoids first-pass liver exposure, but the 2026 RA cohort could not show whether patches lowered its observed VTE risk. “Lower-risk route” is not “risk-free.”^[1][18][17]

RA starts with a higher clot-risk baseline

A 2024 meta-analysis pooled 14 observational studies covering 602,760 people with RA. Compared with people without RA, the pooled relative risks were:^[19]

• VTE: 1.57 (95% CI 1.41–1.76);
• DVT: 1.58 (95% CI 1.26–1.97);
• pulmonary embolism: 1.57 (95% CI 1.30–1.88).

The studies were heterogeneous, so there is no single honest absolute rate that applies to every woman with RA. Age, recent diagnosis, hospitalization, surgery, mobility, obesity, smoking, prior clot, medication, and disease activity all move the baseline.

Disease activity is not background noise

In a large Swedish RA cohort, one-year VTE risk rose from 0.52% in remission to 1.08% in high disease activity. High disease activity carried about twice the risk of remission after adjustment.^[20]

That gives you something concrete to do. Getting RA under control is part of the clot-risk conversation. It does not make HRT automatically safe, but it means disease activity belongs in the decision rather than sitting off to the side.

What the route guidance actually says

The ACR reproductive-health guideline appendix states that, when HRT is otherwise appropriate in a patient with rheumatic and musculoskeletal disease, it is reasonable to consider transdermal estrogen as initial therapy because general-population evidence shows lower VTE risk than oral estrogen.^[1]

The Menopause Society’s 2022 position statement makes the broader point: non-oral routes and lower doses may reduce VTE and stroke risk, while also acknowledging that randomized head-to-head outcome trials by route are lacking.^[18]

That is stronger than “patches are just a preference.” It is weaker than “patches are proven safe in RA.”

So, patch or pill?

For a woman with RA, these are the facts worth carrying into the consult:

• the ACR gives a real reason to discuss transdermal estrogen first when HRT is otherwise appropriate;
• two of the four older RA-specific randomized cohorts used transdermal therapy and did not find worsening of measured RA activity;
• the 2026 RA clot study included both oral and transdermal users but could not compare them;
• route cannot cancel a personal history of thrombosis, APS, high disease activity, immobility, surgery, or another major risk factor.

The useful question is not, “Can I have the patch?” It is: “Why are you choosing this route in my risk context, and which part of that answer comes from RA-specific evidence versus general menopause evidence?”

---

Can you take HRT with methotrexate, biologics, a JAK inhibitor, or steroids?

Answer capsule: The important issue is rarely a simple drug-interaction flag. JAK inhibitors add a thrombosis warning; methotrexate and leflunomide make liver status relevant; glucocorticoids trigger a separate fracture-risk plan; and modern biologic-plus-HRT combinations have not been tested in randomized RA trials. Your medication list changes the review, not necessarily the answer.^[21][22][23]

This is the section most women need and almost nobody builds.

The JAK inhibitor line is the one to take seriously

If you use tofacitinib (Xeljanz), baricitinib (Olumiant), or upadacitinib (Rinvoq), thrombosis is already part of the medication’s safety framework. US JAK-inhibitor labels carry boxed warnings that include thrombosis, and the current US Xeljanz label tells prescribers to avoid the drug in patients at increased thrombosis risk.^[21][24]

The current European product information for tofacitinib goes one step further: it lists combined hormonal contraceptives or hormone replacement therapy among VTE risk factors that require attention. The EMA and MHRA later applied class-wide restrictions and risk minimization across JAK inhibitors used for chronic inflammatory disorders.^[22][25][26]

What that means: it is not an automatic ban on HRT. It is a reason the menopause prescriber should not make the route decision without the rheumatologist knowing what is being added.

The RA medication handoff table

RA medication	Verified safety issue that matters here	What it changes in the HRT conversation
JAK inhibitors — tofacitinib, baricitinib, upadacitinib	US boxed thrombosis warnings; EU/UK materials explicitly identify HRT as a VTE risk factor	Rheumatology should be involved before systemic HRT. Route, dose, disease activity, and other clot risks become clinical questions, not preferences
Glucocorticoids — prednisone or equivalent for more than three months	Current ACR guidance triggers fracture-risk assessment at doses as low as 2.5 mg/day prednisone-equivalent when use is expected to exceed three months	Build a separate glucocorticoid-induced osteoporosis plan. Do not ask HRT to do that whole job
Methotrexate or leflunomide	Both require liver monitoring; a current estradiol transdermal-system label lists hepatic impairment or disease as a contraindication[27][28][29]	Bring current liver results and the exact hormone product. This is not proof of a direct interaction, but liver status is a live variable
TNF inhibitors and other biologics — adalimumab, etanercept, abatacept, rituximab, tocilizumab and others	No modern randomized trial has specifically tested HRT alongside these biologics in women with RA	Absence of a listed direct interaction is not the same as combination-specific safety evidence. Give both prescribers the complete list
Hydroxychloroquine or sulfasalazine	No RA-specific HRT combination trial establishes a special risk signal	Usually fewer route-specific questions than with a JAK inhibitor, but the full history still matters
NSAIDs	Their major issues are gastrointestinal, kidney, cardiovascular, and bleeding considerations rather than a known estrogen metabolism interaction	Keep them on the medication list; do not treat them as a reason to change HRT on your own

Two rules matter here.

First, this is a safety map built from labels and guidelines. It is not a personalized interaction check.

Second: never stop, pause, or change a DMARD because of anything on this page. That decision belongs to your rheumatologist.

Take the drug question with you instead of walking in cold. Find My HRT Path can route you to the care model that best fits your symptoms, state, insurance, and safety history. Then use the medication table above to make the first visit specific rather than vague.

---

Is it an RA flare, or is it menopause?

Answer capsule: Menopause and inflammatory arthritis can overlap in fatigue, stiffness, sleep disruption, low mood, brain fog, and joint pain. Visible swelling, warmth, prolonged morning stiffness, a symmetric small-joint pattern, and steadily progressive symptoms raise more concern for inflammatory activity. There is no single blood test that can diagnose or rule out RA by itself.^[30]

No CTA in this section. If you are in it, you need assessment, not a quiz.

What overlaps

Both menopause and RA can involve:

• aching or stiff joints;
• fatigue;
• disrupted sleep;
• concentration problems;
• low mood;
• reduced exercise tolerance;
• dry eyes, dry mouth, or genital dryness when Sjögren’s or genitourinary syndrome is also present.

That overlap is why women get bounced between explanations. It is also why “my joints improved on HRT” cannot diagnose what the joint problem was.

What clinicians use to separate them

A rheumatology assessment usually looks at the whole pattern:

• whether small joints are affected symmetrically;
• whether there is visible or palpable swelling, warmth, or synovitis rather than pain alone;
• how long morning stiffness lasts;
• whether symptoms are steadily progressing;
• ESR and CRP, which can support inflammation but can also be normal in RA;
• rheumatoid factor and anti-CCP antibodies, neither of which is a standalone diagnosis;
• imaging when the examination and blood work do not settle the question.

There is no single RA test. Diagnosis is a clinical judgment assembled from history, examination, laboratory findings, and sometimes imaging.^[30]

When to stop reading and get seen

New visible joint swelling, persistent warmth, a loss of hand function, or symptoms that worsen over weeks deserve assessment before a hormone decision. Untreated inflammatory arthritis can damage joints; hormone therapy cannot substitute for disease-modifying treatment.

And if you have sudden chest symptoms, breathlessness, coughing blood, fainting, or new one-sided leg swelling, that is not a routine rheumatology appointment. It is urgent care.

The loop this closes

Some observational studies may count women who already had early, unrecognized inflammatory symptoms when HRT began. That is one plausible reason HRT use can appear before an RA diagnosis in health-record data.

The answer is not to fear HRT. The answer is to get swollen or progressive joints assessed first, then make the menopause decision on its own evidence.

To find a rheumatologist, use the American College of Rheumatology’s Find a Rheumatology Professional directory or the Arthritis Foundation’s Find a Doctor directory. We do not earn anything from either.

---

HRT, rheumatoid arthritis, steroids, and bone: what is the difference?

Answer capsule: Systemic estrogen is FDA-approved in specific products for prevention of postmenopausal osteoporosis, and older RA trials recorded bone-density gains. But HRT does not replace the current ACR pathway for glucocorticoid-induced osteoporosis. Long-term prednisone creates a separate assessment and treatment decision even when HRT is appropriate for menopause symptoms.^{[10][9][23][31]}

Most pages collapse these into one bone argument. That is how you end up with a promise that does not hold.

The question	The accurate answer
Can systemic HRT prevent postmenopausal bone loss?	Yes, specific FDA-approved systemic estrogen products carry a prevention indication, and The Menopause Society states that hormone therapy prevents bone loss and fracture. When bone prevention is the only reason for prescribing, product labels generally direct clinicians to consider non-estrogen options as well.[18][31]
Did HRT improve bone density in women with RA?	Yes, in older randomized cohorts. The Hall cohort reported lumbar-spine BMD +2.22% with HRT versus −1.19% in controls, and the D’Elia cohort found gains at multiple skeletal sites.[10][9]
Is HRT the current ACR treatment pathway for glucocorticoid-induced osteoporosis?	No. The 2022 ACR guideline uses fracture-risk assessment and, when treatment is indicated, options such as bisphosphonates, denosumab, or anabolic therapy according to risk and patient factors. It does not position menopausal HRT as a substitute for that pathway.[23]

What the current glucocorticoid guideline changes

For adults beginning or continuing at least 2.5 mg/day of prednisone-equivalent for more than three months, the ACR recommends an initial fracture-risk assessment. Bone mineral density testing with vertebral-fracture assessment or spine imaging should be obtained as soon as practical, with follow-up based on risk and continued exposure.^[23]

The fixed treatment ladder in the 2017 guideline was superseded. The current 2022 guidance is risk-stratified and uses shared decision-making rather than one rigid sequence.

What that means if you take prednisone

If long-term glucocorticoids are part of your RA treatment, HRT may still address menopausal symptoms and one layer of postmenopausal bone loss. It does not answer the glucocorticoid layer by itself.

You need two questions:

1. “What is my menopause-treatment plan?”
2. “What is my glucocorticoid-induced fracture-prevention plan?”

Two overlapping problems. Two separate decisions.

The squeeze worth naming

RA can raise fracture risk through inflammation, reduced mobility, and glucocorticoid exposure. Early or surgical menopause can add another layer.

Which means the women carrying the most stacked bone risk are often the same women being told only about the possible harms of treatment.

That is not an argument that everyone should take HRT. It is an argument that the risk of not treating symptoms and bone loss belongs in the room too.

---

Can you use vaginal estrogen if you have RA or Sjögren’s?

Answer capsule: Yes, RA does not automatically rule out low-dose vaginal estrogen. Genitourinary syndrome of menopause and secondary Sjögren’s can both contribute to dryness, irritation, painful sex, and urinary symptoms. Low-dose vaginal estrogen has minimal systemic absorption and is a separate clinical decision from systemic HRT, but the current label for the exact product still matters.^[18][32]

This is the most under-served question in the whole topic, and often the most tractable.

Genitourinary syndrome of menopause (GSM) describes vaginal and vulvar dryness, burning, irritation, pain with sex, and urinary symptoms linked to estrogen loss. Secondary Sjögren’s can coexist with RA and adds an autoimmune dryness mechanism. One symptom can therefore have two contributors, and replacing local estrogen does not treat Sjögren’s itself.^[32]

Why low-dose vaginal estrogen is a different decision

Low-dose vaginal tablets, inserts, rings, and creams are intended for local symptoms. The Menopause Society states that low-dose vaginal estrogen has minimal systemic absorption and recommends local therapy when GSM is the treatment target and systemic HRT is not otherwise indicated.^[18]

That does not mean every product has identical exposure, dosing, warnings, or instructions. It means a woman whose main problem is painful dryness may not need the same whole-body decision as a woman seeking relief from hot flashes and night sweats.

What it can and cannot do

Symptom pattern	What local estrogen may address	What it does not address
Vaginal or vulvar dryness, irritation, painful sex	Local tissue symptoms related to menopause	RA inflammation or Sjögren’s disease activity
Urinary urgency, irritation, recurrent urinary symptoms linked to GSM	Genitourinary tissue changes	A urinary infection that needs diagnosis and treatment
Hot flashes, night sweats, whole-body sleep disruption	Usually not enough on its own	Systemic vasomotor symptoms

If dryness and painful sex are the main burden, local treatment may be the smaller, cleaner first decision. If your life is being wrecked by hot flashes, night sweats, and systemic sleep disruption, it will not solve that half.

The 2026 FDA label update needs exact-product language

On February 12, 2026, FDA had approved revised prescribing information for six named products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. Estring was the low-dose vaginal product in that first group. FDA also said additional products could be updated later.^[31]

That is why it is inaccurate to say “the FDA changed every vaginal estrogen label.” It did not do so all at once. Check the current prescribing information for the exact product you receive.

For a deeper route-by-route guide, see vaginal estrogen.

---

What do the guidelines say about HRT and rheumatoid arthritis?

Answer capsule: The ACR’s reproductive-health guideline does not treat RA as an automatic HRT contraindication. For postmenopausal women with rheumatic disease who do not have lupus or positive antiphospholipid antibodies, have no ordinary HRT contraindication, have significant symptoms, and want treatment, the guideline supports HRT as good practice. It also gives a reason to consider transdermal estrogen first.^[1]

Where RA sits in the ACR framework

The ACR separates the menopause decision mainly by lupus and antiphospholipid-antibody status, not by placing every autoimmune diagnosis in one bucket.

For a woman with RA who does not have SLE, APS, or known positive antiphospholipid antibodies, the guideline does not create a rheumatology-specific prohibition. Ordinary HRT contraindications and individual cardiovascular, clot, cancer, liver, and bleeding history still apply.^[1]

Two limits matter:

1. A good-practice statement that HRT may be used when indicated is not a recommendation that every woman with RA should take it.
2. The guideline’s evidence review predates the 2024 incidence cohort, the 2026 incidence meta-analysis, and the 2026 RA-specific clot study.

The guideline opens the door. The newer data tell you what has to be discussed before walking through it.

What The Menopause Society says

The Menopause Society’s 2022 position statement does not contain a specific RA recommendation. Its broader position is that the benefit-risk balance is most favorable for many healthy symptomatic women younger than 60 or within 10 years of menopause onset, after contraindications and personal risks are reviewed. It also states that route and dose can matter, with non-oral routes potentially reducing VTE and stroke risk.^[18]

We are not borrowing that general statement and pretending it is RA-specific. The RA-specific evidence and rheumatology guideline stay separate.

Why two specialists can give you two different answers

Your rheumatologist sees disease activity, mobility, vascular risk, glucocorticoid exposure, and DMARD safety.

Your menopause prescriber sees hot flashes, sleep loss, genital symptoms, endometrial protection, product choice, and quality of life.

Neither owns the whole decision. That is why this stalls.

Question	Who should answer it
How active is my RA, and what does that mean for my baseline clot risk?	Rheumatology
Does my JAK inhibitor or another medication add a specific concern?	Rheumatology, with the product label in hand
Does my history give a reason to test for antiphospholipid antibodies?	Rheumatology — not a self-ordered screening panel
Do my glucocorticoids require a formal fracture-risk assessment?	Rheumatology or primary care
Which menopause symptoms are we treating?	Menopause prescriber
Is local or systemic treatment needed?	Menopause prescriber
Which estrogen route fits the combined risk picture?	Menopause prescriber informed by rheumatology
If I have a uterus, what protects the endometrium?	Menopause prescriber
Who monitors what, and who do I contact if symptoms or RA activity change?	Both — get the handoff in writing

You should not have to choose between taking menopause seriously and taking rheumatoid arthritis seriously. Splitting the questions is what turns “my doctors disagree” into a workable plan.

---

Where can women with rheumatoid arthritis start HRT care online?

Answer capsule: Online menopause care may be a reasonable starting model when RA is diagnosed and stable, there is no vascular safety flag, and the service provides a live clinician visit with full medication review. It cannot replace rheumatology, examination of newly swollen joints, or in-person assessment after a clot, stroke, heart attack, APS, or uncontrolled disease.

First, find your starting row

Your situation	Where to start
Stable RA, clear menopause symptoms, no personal DVT/PE/stroke/heart-attack history, no known APS/aPL	A live menopause visit may be reasonable, with your complete RA medication list
Stable RA while taking a JAK inhibitor	Contact rheumatology first or arrange a coordinated decision before systemic HRT
Long-term glucocorticoids or concern about fractures	Menopause care plus a separate ACR-guided bone-risk assessment
New swelling, warmth, progressive hand or foot symptoms, or uncertain diagnosis	In-person primary care or rheumatology first
Personal DVT, PE, stroke, heart attack, known APS, or positive aPL	In-person risk review; do not use a telehealth questionnaire as the deciding step
Main problem is vaginal dryness or painful sex	Ask whether low-dose vaginal estrogen is enough; see vaginal estrogen
HRT is not appropriate or not what you want	Review nonhormonal options

What an online service must do for this situation

We apply The HRT Index Verification Standard to provider research: we read every published price, separate FDA-approved from compounded options, verify state availability and insurance, and re-check on a fixed schedule — top providers monthly, the full roster quarterly. We evaluate providers on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We do not publish numeric provider scores.

For a woman with RA, the service bar is more specific:

1. a live clinician visit rather than an automated product funnel;
2. a full medication and vascular-history review before prescribing;
3. access to FDA-approved non-oral estrogen options when clinically appropriate;
4. clear separation of FDA-approved and compounded products;
5. a plan for endometrial protection when systemic estrogen is used in a woman with a uterus;
6. transparent care fees and clarity about what medication and lab costs are excluded;
7. an explicit route back to rheumatology or in-person care when the case exceeds the service;
8. no promise that HRT will treat RA.

No online menopause provider we verified is a substitute for a rheumatologist. The useful question is which care model gives your menopause decision the best chance of being reviewed properly.

Provider-stated versus verified: the two online starting models that fit best

Provider details verified September 3, 2026. Pricing, insurance participation, state coverage, formularies, and program terms can change. Confirm them before booking.

Provider	Provider-stated care model	Price and coverage verified	Medication disclosure	RA-specific fit	Material limitation
Midi Health	Live virtual visits with menopause-focused clinicians; available in all 50 states	Most PPO plans in network; coverage varies. Self-pay is $250 for the initial visit and $150 for continued-care visits. Midi does not participate in Medicaid/Medi-Cal and says it cannot treat those beneficiaries, even self-pay. Medicare beneficiaries may self-pay, but Midi visits and related services cannot be submitted to Medicare.[33]	Midi promotes FDA-approved HRT and also offers some compounded hormone products. Compounded products are not FDA-approved and must be identified separately.[34]	Stronger fit when insurance and a real-time medication discussion matter	Midi does not provide rheumatology care or promise direct specialist coordination. Its mixed formulary means you must ask exactly what product is being prescribed
Sesame Menopause	Online menopause subscription with provider-selected video visits as needed, unlimited messaging, prescriptions sent to a preferred pharmacy, and basic lab work if the provider says it is necessary	$59 per month for care. Medication costs are not included and vary by insurance and pharmacy. Availability and the clinicians shown must be confirmed during intake.[35]	Sesame lists FDA-approved hormonal and nonhormonal prescription options. The prescribing clinician decides what is appropriate; the listed program price does not include medication	Stronger fit for a cash-pay reader who wants ongoing video access at a clearly published care fee	This is an online menopause program, not an in-person exam or rheumatology service. A low care fee does not resolve a complicated clot or DMARD question by itself

Midi Health — when insurance and a live medication review matter most

Midi’s strongest fit here is not that it can “approve” HRT for a woman with RA. It cannot make that promise before a visit, and neither can we.

Its fit is the care model: a live virtual visit, broad national availability, and insurance billing for many PPO members. That gives a clinician a real appointment in which to review your DMARD, disease activity, vascular history, symptoms, uterus status, and route preference together.^[33]

Here is the honest limitation: Midi’s menopause offering is not a pure FDA-approved-only formulary. Midi promotes FDA-approved hormone therapy and also publishes compounded hormone options. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before dispensing.^[34][36]

If a printed FDA label and a standardized product are priorities in a medication-heavy case, say that explicitly during the visit. Ask for the product name, route, dose form, whether it is FDA-approved or compounded, and why that option was chosen.

Midi is also not the route for Medicaid or Medi-Cal beneficiaries under its current policy, and it does not bill Medicare. Those are real exclusions, not fine print.^[33]

If your RA is stable and the live, insurance-oriented model fits: check Midi’s current coverage and bookable visit cost → (affiliate link; we may earn a commission at no extra cost to you). Bring the medication table and clinician questions from this page.

Sesame — when you want a lower published cash-pay care fee

Sesame’s menopause program is currently listed at $59 per month for care, with video visits as needed, unlimited messaging, prescriptions sent to the pharmacy you choose, and basic lab work included when the clinician orders it as part of the program.^[35]

That is a strong price-transparency advantage. The medication itself is not included, and insurance or pharmacy pricing still determines what you pay for a prescription.^[35]

Here is the honest limitation: Sesame is not an in-person exam option. This is an online menopause subscription. It can fit a stable-RA reader who needs an affordable live-video model; it is not the answer for undiagnosed joint swelling, a past clot, APS, uncontrolled RA, or a complex JAK-inhibitor decision that has not reached rheumatology.

If cash-pay care is the binding constraint and your RA safety questions are already under control: see Sesame’s current menopause program and clinician availability → (external provider link). Confirm the monthly term, state availability, labs, and medication cost before enrolling.

Why there is no universal “best provider” on this page

A high-payout asynchronous program can be a perfectly legitimate fit on a simpler menopause page. It is not automatically the right recommendation when a woman’s medication list may include a JAK inhibitor, glucocorticoid, methotrexate, or biologic.

For this intent, care model beats affiliate priority. A live review and a willingness to send the decision back to rheumatology matter more than a fast checkout.

And if your RA is uncontrolled, your joints are newly swollen, you have a major vascular history, or you know you are aPL-positive: online hormone care is not your starting point. That is not a soft no. It is the route that keeps this page honest.

---

What is still unknown about HRT and rheumatoid arthritis?

Answer capsule: The evidence does not answer the questions modern RA patients care about most. There is no randomized trial of HRT alongside a biologic or JAK inhibitor, no RA-specific oral-versus-transdermal comparison, and no randomized clot-safety trial. The strongest disease-activity trials are decades old; the strongest current clot study is observational.

Naming the gaps is more useful than filling them with confidence.

• No randomized trial has tested HRT alongside a modern biologic or JAK inhibitor as the central question. The RA-specific hormone trials were conducted before those medicines became routine.
• No study has compared oral and transdermal estrogen head-to-head within RA. The 2026 cohort included both routes but could not separate their outcomes.
• No randomized trial has established the clot effect of starting HRT in women with RA. The 2026 result comes from health records, not random assignment.
• No trial tells us whether the older RA disease-activity findings apply unchanged to today’s lower-dose products and modern treat-to-target RA care.
• The ACR reproductive-health guideline predates the 2024 and 2026 studies. Its framework remains useful, but it has not formally integrated those results.
• Antiphospholipid-antibody testing is not a universal self-screen before HRT. Whether it is warranted depends on clinical history and belongs with rheumatology.
• Provider formularies and policies change faster than medical guidelines. The exact product, route, price, coverage, and state availability must be checked at the time of care.

If somebody tells you this evidence is settled, they have not read all of it.

---

What should you ask your rheumatologist and menopause prescriber?

Answer capsule: The decision moves fastest when the questions are split by specialty. Rheumatology should define disease activity, medication-related risk, clot context, and glucocorticoid bone risk. The menopause prescriber should define the symptom target, local-versus-systemic need, product, route, endometrial protection, and follow-up plan.

Print this. Save it. Take it with you. It is free and it is not gated.

Ask your rheumatologist

1. How active is my RA right now, and what does that mean for my baseline VTE risk?
2. Does my current DMARD create a specific route or clot concern if systemic estrogen is considered?
3. If I take a JAK inhibitor, how do you want the menopause prescriber to account for its thrombosis warning?
4. Does my personal or family history give a clinical reason to test for antiphospholipid antibodies?
5. If I use prednisone or another glucocorticoid, has my fracture risk been assessed under the current ACR guideline?
6. Are you willing to share your assessment with the clinician managing my menopause symptoms?

Ask your menopause prescriber

1. Which symptoms are we treating, and what outcome will tell us the treatment is working?
2. Do I need systemic treatment, or could low-dose vaginal therapy address the main problem?
3. Which route are you recommending, and why in the context of RA and my medication list?
4. Is the exact product FDA-approved or compounded?
5. If I have a uterus, what protects the endometrium in this regimen?
6. What are the stop signs, follow-up timing, and plan if my RA activity changes?
7. Which costs are for care, labs, and medication, and which may be billed to insurance?
8. If you are not comfortable prescribing, what specific question needs to be answered before we revisit it?

Bring these records

• every prescription, over-the-counter medicine, and supplement with doses;
• your most recent rheumatology note or disease-activity assessment if available;
• recent CBC, liver, kidney, ESR, and CRP results if your clinicians already ordered them;
• your latest DEXA scan and any fracture history;
• your own history of DVT, PE, stroke, heart attack, migraine with aura, smoking, surgery, prolonged immobility, cancer, and liver disease;
• close-family clot history;
• the date of your last menstrual period, hysterectomy, or oophorectomy, if relevant;
• a short list of the symptoms you most need treated.

Want a starting route before you book? Find My HRT Path uses your symptoms, priorities, safety history, treatment preferences, state, and insurance situation to show one best-fit online route and two backups. It takes about 90 seconds, requires no email, and clearly labels FDA-approved and compounded options.

---

Frequently asked questions

Can I take HRT if I have rheumatoid arthritis?

Rheumatoid arthritis is not an automatic bar to menopausal hormone therapy. The decision changes with your disease activity, clot and cardiovascular history, antiphospholipid-antibody status, liver health, current medication, symptom target, and proposed route. The ACR supports considering HRT when it is otherwise indicated in postmenopausal women with rheumatic disease who do not have lupus or positive antiphospholipid antibodies and have no standard contraindication.^[1]

Does HRT cause rheumatoid arthritis?

Observational studies show a small association with being diagnosed with RA later. The 2026 pooled estimate was a rate ratio of 1.15, while the WHI randomized analysis found a non-significant hazard ratio of 0.74. That combination does not establish that HRT causes RA.^[14][11]

Will HRT cause an RA flare?

The four RA-specific randomized trial cohorts did not find statistically significant worsening in the disease-activity outcomes they measured. That is reassuring, but “flare” was not a standardized endpoint across all studies, the trials were small and old, and they did not test women taking today’s full range of biologics and JAK inhibitors.^[6][7][8][9]

Does HRT help rheumatoid arthritis?

HRT is not an RA treatment and should not replace a DMARD. Some randomized RA studies found improvements in tenderness, wellbeing, inflammatory measures, bone density, or radiographic progression, while another found no disease benefit. The evidence is too inconsistent and dated to prescribe menopausal hormone therapy for RA control.^[6][7][8][9]

Can I take HRT with methotrexate?

The current evidence does not establish a universal direct methotrexate–HRT prohibition. The practical issue is the whole safety picture: methotrexate requires liver monitoring, and a current estradiol transdermal-system label lists hepatic impairment or disease as a contraindication.^[27][29] Bring your current liver results and complete medication list to the prescriber; do not change methotrexate because of this page.

Can I take HRT with a biologic such as Humira or Enbrel?

There is no RA-specific randomized trial designed to answer that combination question. We did not find a class-wide estrogen interaction statement in the prescribing information reviewed for common biologics, but absence of a listed interaction is not an individualized clearance. The prescriber still needs your infection history, cardiovascular and clot history, disease activity, and complete medication list.

Can I take HRT with Rinvoq, Xeljanz, or Olumiant?

This combination needs a deliberate clot-risk review. JAK inhibitors carry US boxed warnings that include thrombosis, and current European and UK risk materials explicitly include hormone replacement therapy among VTE risk factors. That is not an automatic no, but it is a strong reason to involve rheumatology before the route is chosen.^[24][22][26]

Is a patch safer than a pill if I have RA?

No RA study has compared oral and transdermal estrogen head-to-head for clot outcomes. General menopause guidance and the ACR framework make a non-oral route a reasonable discussion point when HRT is otherwise appropriate, but the 2026 RA cohort could not prove that patches eliminate the excess VTE signal.^[1][18][17]

Does rheumatoid arthritis increase blood-clot risk?

Yes. A 2024 meta-analysis of 14 studies covering 602,760 people with RA found a pooled relative risk of 1.57 for VTE, 1.58 for DVT, and 1.57 for pulmonary embolism compared with people without RA. Higher RA disease activity is associated with higher absolute risk.^[19][20]

What did the 2026 RA and HRT clot study find?

It found VTE rates of 6.49 per 1,000 person-years among 2,187 MHT initiators and 3.30 per 1,000 person-years among 8,205 matched non-initiators, with an adjusted hazard ratio of 1.92. The rate difference was 3.19 per 1,000 person-years, or one additional event per roughly 313 person-years under the study’s observed rates. It was observational and could not compare routes.^[17]

Will HRT protect my bones if I take prednisone?

Systemic menopausal hormone therapy can prevent postmenopausal bone loss, and older RA trials found bone-density gains. It does not replace a glucocorticoid-induced osteoporosis plan. Under the current ACR guideline, adults taking at least 2.5 mg/day of prednisone equivalent for more than three months should have fracture risk assessed, with treatment selected by risk category.^[10][9][23]

How do I know whether joint symptoms are an RA flare or menopause?

You often cannot separate them by symptom alone. Visible swelling, warmth, prolonged morning stiffness, a symmetric small-joint pattern, rising inflammatory markers, and steady progression make inflammatory activity more concerning, but RA diagnosis and flare assessment require clinical judgment. New or worsening swelling deserves assessment before a hormone plan is used as the explanation.^[30]

Does menopause make rheumatoid arthritis worse?

Menopause is associated with worse physical function in women whose RA began before menopause. In the 2018 longitudinal study, postmenopausal status was associated with a 0.68-point worse HAQ score after adjustment. That is an association with function, not proof that menopause directly accelerates joint inflammation in every woman.^[2]

Can I use vaginal estrogen if I have RA or Sjögren’s disease?

RA itself is not a labeled reason to reject low-dose vaginal estrogen. Local treatment is a separate decision from systemic HRT and is aimed at vaginal and urinary symptoms, not hot flashes or RA activity. Because FDA labeling changes have been product-specific, check the current label and patient information for the exact product you are prescribed.^[31][18]

My rheumatologist and menopause prescriber disagree. Who decides?

Neither clinician owns every part. Rheumatology should define disease activity, medication-specific risk, clot context, and glucocorticoid bone risk. The menopause prescriber should define the symptom target, local-versus-systemic need, product, route, endometrial protection, and follow-up. Ask them to document the unanswered question instead of passing you back and forth.

---

How this page was made

Who: The HRT Index editorial team. No clinician reviewed this page, and no clinician’s name or credentials have been added to make it look otherwise.

How: We read the randomized RA reports, cohort studies, meta-analyses, ACR guidance, current FDA/EMA/MHRA materials, current US prescribing information, and provider-owned pricing and policy pages. We checked duplicate reporting, separated parent-trial size from the actual RA subgroup, dated provider facts, and labeled editorial calculations and interpretations.

Why: A woman with RA deserves better than either extreme: “autoimmune disease means no hormones” or “patches solve everything.” The evidence supports neither. The useful answer is the route-and-review framework on this page.

What we do not do: We do not fabricate clinical review, testimonials, first-person treatment experience, or numeric provider scores. We do not treat compounded medication as FDA-approved or imply that it has passed the same premarket review. We do not turn an observational association into a personal risk prediction.

Affiliate disclosure: The HRT Index may earn a commission from some links on this page, at no extra cost to you. Affiliate status does not change the medical evidence, the provider facts we verify, or the situations we route away from online care. See the full affiliate disclosure.

Corrections and review schedule: Medical and regulatory claims are re-verified quarterly and after a material FDA, EMA, MHRA, ACR, or Menopause Society update. Provider price, coverage, visit model, formulary language, and state availability are re-checked monthly for featured providers. The next scheduled full review is December 2026.

---

Sources

Rheumatoid arthritis, menopause, and randomized evidence

Risk of developing rheumatoid arthritis

Blood-clot risk and route

Rheumatology and bone guidelines

Medication-label sources

JAK-inhibitor and hormone-product regulation

Provider facts checked September 3, 2026

---

Still not sure which HRT program is right for you? Take The HRT Index’s free, about-90-second Find My HRT Path quiz.

¹ American College of Rheumatology. 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases, including the menopause evidence appendix.

² Mollard E, et al. “The impact of menopause on functional status in women with rheumatoid arthritis.” Rheumatology. 2018;57(5):798–802. DOI: 10.1093/rheumatology/kex526.

³ Mollard E, et al. “Estrogen replacement therapy and physical function in rheumatoid arthritis.” Rheumatology. 2026. DOI: 10.1093/rheumatology/keag197.

⁴ National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid Arthritis.

⁵ Hazes JMW, Coulie PG, Geenen V, et al. “Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use.” Rheumatology. 2011;50(11):1955–1968. PubMed.

⁶ van den Brink HR, et al. “Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis.” Annals of the Rheumatic Diseases. 1993;52:862–865. PubMed.

⁷ MacDonald AG, Murphy EA, Capell HA, et al. “Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study.” Annals of the Rheumatic Diseases. 1994;53(1):54–57. PubMed.

⁸ Hall GM, Daniels M, Huskisson EC, Spector TD. “A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis.” Annals of the Rheumatic Diseases. 1994;53(2):112–116. PubMed.

⁹ Forsblad D’Elia H, et al. “Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis.” Journal of Rheumatology. 2003;30(7):1456–1463. PubMed.

¹⁰ Hall GM, Daniels M, Doyle DV, Spector TD. “Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids.” Arthritis & Rheumatism. 1994;37(10):1499–1505. PubMed.

¹¹ Walitt B, et al. “Effects of postmenopausal hormone therapy on rheumatoid arthritis: the Women’s Health Initiative randomized controlled trials.” Arthritis & Rheumatism. 2008;59(3):302–310. Full text.

¹² Zhang X, et al. “The effect of hormone replacement therapy on musculoskeletal pain in menopausal women: A systematic review and meta-analysis.” Post Reproductive Health. 2026;32(1):52–68. DOI: 10.1177/20533691251403087.

¹³ Jiang LQ, et al. “Hormonal and reproductive factors in relation to the risk of rheumatoid arthritis in women: a prospective cohort study with 223,526 participants.” RMD Open. 2024;10:e003338. DOI: 10.1136/rmdopen-2023-003338.

¹⁴ Guimarães C, et al. “Hormone therapy in menopause increases rheumatoid arthritis risk: a systematic review and meta-analysis.” Seminars in Arthritis and Rheumatism. 2026. DOI: 10.1016/j.semarthrit.2026.152935.

¹⁵ Eun Y, et al. “Menopausal factors and risk of seropositive rheumatoid arthritis in postmenopausal women: a nationwide cohort study of 1.36 million women.” Scientific Reports. 2020;10:20793. DOI: 10.1038/s41598-020-77841-1.

¹⁶ British Menopause Society. New Study — HRT & rheumatoid arthritis. January 2024.

¹⁷ Czachorowski M, et al. “Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England.” Rheumatology Advances in Practice. 2026;10(3):rkag087. DOI: 10.1093/rap/rkag087.

¹⁸ The North American Menopause Society. “The 2022 hormone therapy position statement.” Menopause. 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028.

¹⁹ Fazal ZA, et al. “Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies.” BMC Rheumatology. 2024;8:11. DOI: 10.1186/s41927-024-00376-9.

²⁰ Molander V, et al. “Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.” Annals of the Rheumatic Diseases. 2021;80:169–175. PubMed.

²¹ Pfizer. XELJANZ/XELJANZ XR US Prescribing Information.

²² European Medicines Agency. Xeljanz: EPAR product information.

²³ American College of Rheumatology. 2022 Guideline Summary for Prevention and Treatment of Glucocorticoid-Induced Osteoporosis; Humphrey MB, et al. Arthritis & Rheumatology. 2023. DOI: 10.1002/art.42646.

²⁴ US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

²⁵ European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders.

²⁶ UK Medicines and Healthcare products Regulatory Agency. JAK inhibitors: new measures to reduce risks.

²⁷ DailyMed. Methotrexate tablet prescribing information. Current label accessed September 3, 2026.

²⁸ DailyMed. Leflunomide tablet prescribing information. Current label accessed September 3, 2026.

²⁹ DailyMed. Estradiol transdermal system prescribing information. Current label accessed September 3, 2026.

³⁰ National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take.

³¹ US Food and Drug Administration. Menopausal hormone therapies: updated prescribing information. February 12, 2026.

³² National Institute of Arthritis and Musculoskeletal and Skin Diseases. Sjögren’s Disease.

³³ Midi Health. Hormone replacement therapy, insurance and coverage, and pricing. Provider-stated facts checked September 3, 2026.

³⁴ Midi Health. Estrogen shortage and treatment options. Provider-stated formulary language checked September 3, 2026.

³⁵ Sesame. Menopause treatment. Provider-stated program terms checked September 3, 2026.

³⁶ US Food and Drug Administration. Compounding and the FDA: Questions and Answers.